Skip to Navigation

Product Information

The first medical nutrition product targeting synapse loss

  • Clinically proven to improve memory in patients with early Alzheimer‘s Disease [1,2]
  • Well tolerated and high product compliance [1-3]
  • Recommended to be taken one a day, every day [1,2]
  • Available in a convenient ready to drink 125 ml bottle: vanilla and strawberry flavours

Souvenaid indication

  • Souvenaid is a Food for Special Medical Purpose (FSMP) for the dietary management of early Alzheimer’s disease which must be used under medical supervision. 
  • Souvenaid has been clinically proven to significantly improve memory in randomised controlled trials conducted in patients with mild to very mild Alzheimer’s disease [1,2]. 

Souvenaid dosage

  • Souvenaid is recommended to be taken once-daily, on an ongoing basis [1,2] under medical supervision.

Souvenaid patented combination of nutrients 

  • Souvenaid contains a patented combination of nutrients, commonly referred under the trademark Fortasyn ConnectTM, which provides nutritional precursors and cofactors that work together to support synapse formation.
    • DHA (docosaexhexaenoic acid), EPA (eicosapentaenoic acide), UMP (uridine monophosphate) and choline are precursors required to enhance neuronal  membrane formation
    • B-vitamins, vitamin C, E, selenium and phospholipids serve as cofactors by enhancing the bioavailability of those precursors

 

Component Amount (per 125ml) Food equivalent*
DHA 1200 mg 82 g Salmon, Atlantic cooked dry heat
EPA 300 mg 56 g Anchovies, European raw
UMP** 625 mg 482 g Tomato soup
Choline 400 mg 178 g Egg, whole hard-boiled
Folate 400 mcg 268 g Asparagus, green cooked
Vitamin B6 1 mg 74 g Sunflower seeds
Vitamin B12 100 mcg 100 g Beef, steak
Vitamin C 80 mg 158 g Orange
Vitamin E 40 mg 153 g Almonds
Selenium 60 mcg 3 g Brazil nuts
Phospholipids 106 mg 14 g Butter 

* The table shows the amounts of foods known to contain the key ingredients (UMP, EPA, DHA, phospholipids and choline) in high amounts. Some additional vitamins and minerals in Souvenaid are not shown in this table, see the full nutritionnal composition below. Only 1 nutrient per food equivalent is taken into account. Bioavailability of the nutrients provided through either the food item shown in the table, or Souvenaid has not been directly compared.

** No studies have shown elevated  plasma uridine levels from sources other than mother's milk and infant formula. 

EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; UMP = uridine monophosphate

Souvenaid nutritional composition

Average contents per 100 ml  
Energy 420 kJ / 100 kcal 
Protein (12 En%) 3.0 g
Carbohydrate (36 En%) 13.2 g
- Sugars 6.4 g
-- Lactose <0.025 g
Fat (36 En%) 3.9 g
- Saturates 1.3 g
- Monounsaturates 0.7 g
- Polyunsaturates 1.5 g
-- Eicosapentaenoic acid (EPA) 240 mg
-- Docosapentaenoic acid (DHA) 960 mg
Dietary fibre (0 En%) 0 g
Minerals and trace elements:  
Sodium 100 (4.3) mg (mmol)
Potassium 150 (3.8) mg (mmol)
Chloride 125 (3.5) mg (mmol)
Calcium 80 (2.0) mg (mmol)
Phosphorus 70 (2.3) mg (mmol)
Phosphate 217 (2.3) mg (mmol)
Magnesium 20 (0.8) mg (mmol)
Iron 1.6 mg
Zinc 1.2 mg
Copper 180 µg
Manganese 0.33 mg
Molybdenum 10 µg
Selenium 48 µg
Chromium 6.7 µg
Iodine 13 µg
Vitamins:  
Vitamin A 160 µg-RE
Vitamin D3 0.7 µg
Vitamin E 32 mg α-TE
Vitamin K 5,3 µg
Thiamin (B1) 0.15 mg
Riboflavin (B2) 0.16 mg
Niacin (B3) 1.8 mg-NE
Pantothenic acid (B5) 0.53 mg
Vitamin B6 0.80 mg
Folic acid 320 µg
Vitamin B12 2.4 µg
Biotin 4.0 µg
Vitamin C 64 mg
Others:  
Uridine-5'-monophosphate (UMP) 500 mg
Choline 320 mg
Osmolarity 490 mOsml/l

 

 

Souvenaid safety profile and tolerability

  • Souvenaid is well tolerated alone in mild Alzheimer’s disease, and in combination with standard Alzheimer’s disease medication in mild to moderate Alzheimer’s disease, with a side effect profile similar to that of controls in clinical trials [1-3].
  • The safety profile of Souvenaid has been established in three randomised controlled trials involving more than 1000 patients with mild-to-moderate Alzheimer’s disease [1-3]:
    • Souvenaid was well tolerated, with >90% patient compliance
    • No difference in the incidence of serious adverse events was observed between the Souvenaid and control patients receiving standard Alzheimer’s disease medications at a stable dose (AChEI and/or NMDA receptor antagonist)
  • In the clinical trial setting:
    • No clinically relevant differences in serious adverse events and liver and renal safety parameters were observed between Souvenaid and control groups
    • No serious adverse events were related to the use of antihypertensives and anticoagulants in combination with Souvenaid, at the recommended dosage
    • No serious adverse events occurred that would indicate contra-indication for diabetic patients. However, Souvenaid contains carbohydrates (16.5 g per bottle, 7.5 g of which are sucroses), and similar to other products containing carbohydrates, it is recommended that patients monitor blood glucose levels as they would normally do, according to their doctor’s advice

Souvenaid recommendation 

  • Souvenaid is a medical nutrition product which must be used under medical supervision
  • To aid patient compliance, it is recommended that Souvenaid be consumed at the same time each day as part of the patient’s normal routine, for example with breakfast. 
  • Souvenaid tastes best when served chilled 

Souvenaid availability

  • Souvenaid is available as a convenient once-daily drink.
  • The small volume bottle (125 ml) is ready to drink and available in two flavours (vanilla and strawberry). 
  • Souvenaid can be purchased in packs of 4 bottles. 
  • Patients may purchase Souvenaid over the counter in pharmacies after consultation with their doctor.
  • Souvenaid is available in Argentina, Australia, Austria, Belgium, Brazil, Germany, Ireland, Italy, the Netherlands, United Kingdom, Spain.
  • Souvenaid has recently been launched in Finland, Poland and Sweden. 

For more information on how to recommend Souvenaid in your country, please click here to visit your local Souvenaid website

References

  1. Scheltens P, et al. Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement. 2010;6:1-10.e1.
  2. Scheltens P, et al. Efficacy of Souvenaid in mild Alzheimer's disease: results from a randomized, controlled trial. J Alzheimer’s Dis. 2012;31:225–236.
  3. Shah R, et al. Souvenaid® as an add-on intervention in patients with mild to moderate Alzheimer’s Disease using Alzheimer’s Disease medication: results from a randomized, controlled, Double-blind study (S-Connect). CTAD, San Diego, November 2011; J Nutr Health Aging (Nov suppl.).